Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

353 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Chemotherapy for gastric cancer].
Baba H, Kakeji Y, Oki E, Tokunaga E, Ushiro S, Watanabe M, Maehara Y. Baba H, et al. Among authors: tokunaga e. Gan To Kagaku Ryoho. 2003 Nov;30(12):1881-8. Gan To Kagaku Ryoho. 2003. PMID: 14650954 Review. Japanese.
Trastuzumab and breast cancer: developments and current status.
Tokunaga E, Oki E, Nishida K, Koga T, Egashira A, Morita M, Kakeji Y, Maehara Y. Tokunaga E, et al. Int J Clin Oncol. 2006 Jun;11(3):199-208. doi: 10.1007/s10147-006-0575-4. Int J Clin Oncol. 2006. PMID: 16850126 Review.
[A randomized controlled trial to evaluate the effect of adjuvant oral fluoropyrimidine derivative therapy after curative resection for stage II/III rectal cancer-adjuvant chemotherapy trial of S-1 for rectal cancer (ACTS-RC):].
Oki E, Kakeji Y, Yoshida R, Ikeda K, Nishida K, Koga T, Egashira A, Tokunaga E, Morita M, Baba H, Maehara Y. Oki E, et al. Among authors: tokunaga e. Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:138-43. Gan To Kagaku Ryoho. 2006. PMID: 16897990 Clinical Trial. Japanese.
Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari).
Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita T, Yamamoto Y, Ohno S, Toi M. Kawaguchi H, et al. Among authors: tokunaga e. Breast Cancer Res Treat. 2017 Jun;163(3):545-554. doi: 10.1007/s10549-017-4212-x. Epub 2017 Mar 23. Breast Cancer Res Treat. 2017. PMID: 28337663
Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a sub-group analysis of the JBCRG-C06 Safari study.
Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S. Kawaguchi H, et al. Among authors: tokunaga e. Curr Med Res Opin. 2018 Jan;34(1):49-54. doi: 10.1080/03007995.2017.1400426. Epub 2017 Nov 21. Curr Med Res Opin. 2018. PMID: 29095648
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group. Martin M, et al. Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13. Lancet Oncol. 2017. PMID: 29146401 Clinical Trial.
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas MP, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, O'Reilly S, Di Lauro V, Gombos A, Ruhstaller T, Burstein H, Ribi K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber RD, Coates AS, Di Leo A, Regan MM, Goldhirsch A; SOLE Investigators. Colleoni M, et al. Lancet Oncol. 2018 Jan;19(1):127-138. doi: 10.1016/S1470-2045(17)30715-5. Epub 2017 Nov 17. Lancet Oncol. 2018. PMID: 29158011 Clinical Trial.
[Development of a Computer-aided Diagnosis System to Distinguish between Benign and Malignant Mammary Tumors in Dynamic Magnetic Resonance Images: Automatic Detection of the Position with the Strongest Washout Effect in the Tumor].
Miyazaki Y, Tabata N, Taroura T, Shinozaki K, Kubo Y, Tokunaga E, Taguchi K. Miyazaki Y, et al. Among authors: tokunaga e. Nihon Hoshasen Gijutsu Gakkai Zasshi. 2018;74(3):251-261. doi: 10.6009/jjrt.2018_JSRT_74.3.251. Nihon Hoshasen Gijutsu Gakkai Zasshi. 2018. PMID: 29563394 Free article. Japanese.
Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study.
Yamashiro H, Sawaki M, Masuda N, Okumura Y, Takano T, Tokunaga E, Saito T, Sagara Y, Yamazaki K, Kawaguchi Y, Lee T, Ozaki S, Yamagami K, Yamamoto N, Kuroi K, Suwa H, Ohtani S, Ito T, Yasuno S, Morita S, Ohno S, Toi M. Yamashiro H, et al. Among authors: tokunaga e. Breast Cancer (Auckl). 2018 Jul 5;12:1178223418786243. doi: 10.1177/1178223418786243. eCollection 2018. Breast Cancer (Auckl). 2018. PMID: 30013356 Free PMC article.
Clinical significance of evaluating hormone receptor and HER2 protein using cell block against metastatic breast cancer: a multi-institutional study.
Matsui A, Murata Y, Masuda N, Mori K, Takahashi M, Yamashiro K, Aogi K, Maeda S, Itou M, Ozaki S, Kuraoka K, Satou Y, Ichihara S, Tokunaga E, Taguchi K, Watanabe T, Suzuki H, Nagayama A, Nishimura R. Matsui A, et al. Among authors: tokunaga e. Oncotarget. 2019 Oct 1;10(55):5680-5689. doi: 10.18632/oncotarget.27163. eCollection 2019 Oct 1. Oncotarget. 2019. PMID: 31620243 Free PMC article.
Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study.
Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S. Kawaguchi H, et al. Among authors: tokunaga e. Breast Cancer. 2020 May;27(3):389-398. doi: 10.1007/s12282-019-01029-3. Epub 2019 Dec 6. Breast Cancer. 2020. PMID: 31811519 Free PMC article.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I; DESTINY-Breast01 Investigators. Modi S, et al. Among authors: tokunaga e. N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11. N Engl J Med. 2020. PMID: 31825192 Free PMC article. Clinical Trial.
The comparison of the anatomic stage and pathological prognostic stage according to the AJCC 8th edition for the prognosis in Japanese breast cancer patients: data from a single institution.
Tokunaga E, Ijichi H, Tajiri W, Masuda T, Takizawa K, Ueo H, Koga C, Tanaka J, Nakamura Y, Ohno S, Taguchi K, Okamoto M. Tokunaga E, et al. Breast Cancer. 2020 Nov;27(6):1137-1146. doi: 10.1007/s12282-020-01116-w. Epub 2020 May 29. Breast Cancer. 2020. PMID: 32472474 Free PMC article.
Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer.
Goetz MP, Martin M, Tokunaga E, Park IH, Huober J, Toi M, Stoffregen C, Shekarriz S, Andre V, Gainford MC, Price GL, Johnston S. Goetz MP, et al. Among authors: tokunaga e. Oncologist. 2020 Sep;25(9):e1346-e1354. doi: 10.1634/theoncologist.2020-0084. Epub 2020 Jun 24. Oncologist. 2020. PMID: 32536013 Free PMC article. Clinical Trial.
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; OlympiA Clinical Trial Steering Committee and Investigators. Tutt ANJ, et al. N Engl J Med. 2021 Jun 24;384(25):2394-2405. doi: 10.1056/NEJMoa2105215. Epub 2021 Jun 3. N Engl J Med. 2021. PMID: 34081848 Free PMC article. Clinical Trial.
Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study).
Tokunaga E, Masuda N, Yamamoto N, Iwata H, Bando H, Aruga T, Ohtani S, Fujisawa T, Takano T, Inoue K, Suganuma N, Takada M, Aogi K, Sakurai K, Shigematsu H, Kuroi K, Haga H, Ohno S, Morita S, Toi M. Tokunaga E, et al. Cancers (Basel). 2021 Aug 9;13(16):4008. doi: 10.3390/cancers13164008. Cancers (Basel). 2021. PMID: 34439165 Free PMC article.
A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17).
Fukada I, Ito Y, Kondo N, Ohtani S, Hattori M, Tokunaga E, Matsunami N, Mashino K, Kosaka T, Tanabe M, Yotsumoto D, Yamanouchi K, Sawaki M, Kashiwaba M, Kawabata H, Kuroi K, Morita S, Ohno S, Toi M, Masuda N. Fukada I, et al. Among authors: tokunaga e. Breast Cancer Res Treat. 2021 Dec;190(3):425-434. doi: 10.1007/s10549-021-06396-0. Epub 2021 Sep 23. Breast Cancer Res Treat. 2021. PMID: 34554370 Free PMC article. Clinical Trial.
Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Takahashi M, Tokunaga E, Mori J, Tanizawa Y, van der Walt JS, Kawaguchi T, Goetz MP, Toi M. Takahashi M, et al. Among authors: tokunaga e. Breast Cancer. 2022 Jan;29(1):174-184. doi: 10.1007/s12282-021-01295-0. Epub 2021 Oct 18. Breast Cancer. 2022. PMID: 34661821 Free PMC article. Clinical Trial.
Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-C06 Safari study.
Kawaguchi H, Yamamoto Y, Saji S, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yotsumoto D, Toi M, Ohno S. Kawaguchi H, et al. Among authors: tokunaga e. Jpn J Clin Oncol. 2022 May 31;52(6):545-553. doi: 10.1093/jjco/hyac022. Jpn J Clin Oncol. 2022. PMID: 35296894
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA; DESTINY-Breast03 Trial Investigators. Cortés J, et al. N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022. N Engl J Med. 2022. PMID: 35320644 Clinical Trial.
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA; DESTINY-Breast04 Trial Investigators. Modi S, et al. Among authors: tokunaga e. N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35665782 Free PMC article. Clinical Trial.
Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive/HER2-negative post-menopausal advanced breast cancer: an additional analysis of the JBCRG-C06 Safari study.
Kawaguchi H, Yamamoto Y, Saji S, Masuda N, Nakayama T, Aogi K, Anan K, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita T, Yotsumoto D, Toi M, Ohno S. Kawaguchi H, et al. Among authors: tokunaga e. Jpn J Clin Oncol. 2023 Mar 7;53(3):203-211. doi: 10.1093/jjco/hyac184. Jpn J Clin Oncol. 2023. PMID: 36484305
Fulvestrant with or without anti-HER2 therapy in patients in a postmenopausal hormonal state and with ER-positive HER2-positive advanced or metastatic breast cancer: A subgroup analysis of data from the Safari study (JBCRG-C06).
Masuyama M, Masuda N, Kawaguchi H, Yamamoto Y, Saji S, Nakayama T, Aogi K, Anan K, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita T, Yotsumoto D, Toi M, Ohno S. Masuyama M, et al. Among authors: tokunaga e. Cancer Med. 2023 Sep;12(17):17718-17730. doi: 10.1002/cam4.6390. Epub 2023 Aug 1. Cancer Med. 2023. PMID: 37525895 Free PMC article.
Low nuclear grade but not cell proliferation predictive of pathological complete response to docetaxel in human breast cancers.
Miyoshi Y, Kurosumi M, Kurebayashi J, Matsuura N, Takahashi M, Tokunaga E, Egawa C, Masuda N, Kim SJ, Okishiro M, Yanagisawa T, Ueda S, Taguchi T, Tamaki Y, Noguchi S; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Miyoshi Y, et al. Among authors: tokunaga e. J Cancer Res Clin Oncol. 2008 May;134(5):561-7. doi: 10.1007/s00432-007-0319-5. Epub 2007 Oct 16. J Cancer Res Clin Oncol. 2008. PMID: 17938960
Predictive factors for anthracycline-based chemotherapy for human breast cancer.
Miyoshi Y, Kurosumi M, Kurebayashi J, Matsuura N, Takahashi M, Tokunaga E, Egawa C, Masuda N, Kono S, Morimoto K, Kim SJ, Okishiro M, Yanagisawa T, Ueda S, Taguchi T, Tamaki Y, Noguchi S. Miyoshi Y, et al. Among authors: tokunaga e. Breast Cancer. 2010 Apr;17(2):103-9. doi: 10.1007/s12282-009-0152-6. Epub 2009 Aug 6. Breast Cancer. 2010. PMID: 19657712 Review.
Vimentin as a poor prognostic factor for triple-negative breast cancer.
Yamashita N, Tokunaga E, Kitao H, Hisamatsu Y, Taketani K, Akiyoshi S, Okada S, Aishima S, Morita M, Maehara Y. Yamashita N, et al. Among authors: tokunaga e. J Cancer Res Clin Oncol. 2013 May;139(5):739-46. doi: 10.1007/s00432-013-1376-6. Epub 2013 Jan 26. J Cancer Res Clin Oncol. 2013. PMID: 23354842
Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
Yamashita N, Tokunaga E, Kitao H, Hitchins M, Inoue Y, Tanaka K, Hisamatsu Y, Taketani K, Akiyoshi S, Okada S, Oda Y, Saeki H, Oki E, Maehara Y. Yamashita N, et al. Among authors: tokunaga e. Clin Breast Cancer. 2015 Dec;15(6):498-504. doi: 10.1016/j.clbc.2015.06.009. Epub 2015 Jun 18. Clin Breast Cancer. 2015. PMID: 26195437
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
Takashima T, Mukai H, Hara F, Matsubara N, Saito T, Takano T, Park Y, Toyama T, Hozumi Y, Tsurutani J, Imoto S, Watanabe T, Sagara Y, Nishimura R, Shimozuma K, Ohashi Y; SELECT BC Study Group. Takashima T, et al. Lancet Oncol. 2016 Jan;17(1):90-8. doi: 10.1016/S1470-2045(15)00411-8. Epub 2015 Nov 27. Lancet Oncol. 2016. PMID: 26617202 Clinical Trial.
Impact of Expression of Vimentin and Axl in Breast Cancer.
Tanaka K, Tokunaga E, Inoue Y, Yamashita N, Saeki H, Okano S, Kitao H, Oki E, Oda Y, Maehara Y. Tanaka K, et al. Among authors: tokunaga e. Clin Breast Cancer. 2016 Dec;16(6):520-526.e2. doi: 10.1016/j.clbc.2016.06.015. Epub 2016 Jul 5. Clin Breast Cancer. 2016. PMID: 27506606
Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry.
Kataoka A, Iwamoto T, Tokunaga E, Tomotaki A, Kumamaru H, Miyata H, Niikura N, Kawai M, Anan K, Hayashi N, Masuda S, Tsugawa K, Aogi K, Ishida T, Masuoka H, Iijima K, Kinoshita T, Nakamura S, Tokuda Y. Kataoka A, et al. Among authors: tokunaga e. Breast Cancer Res Treat. 2016 Nov;160(1):163-172. doi: 10.1007/s10549-016-3984-8. Epub 2016 Sep 19. Breast Cancer Res Treat. 2016. PMID: 27647460 Free PMC article.
Expression of APOBEC3B mRNA in Primary Breast Cancer of Japanese Women.
Tokunaga E, Yamashita N, Tanaka K, Inoue Y, Akiyoshi S, Saeki H, Oki E, Kitao H, Maehara Y. Tokunaga E, et al. PLoS One. 2016 Dec 15;11(12):e0168090. doi: 10.1371/journal.pone.0168090. eCollection 2016. PLoS One. 2016. PMID: 27977754 Free PMC article.
Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study.
Tanaka K, Masuda N, Hayashi N, Sagara Y, Hara F, Kadoya T, Matsui A, Miyazaki C, Shien T, Tokunaga E, Hayashi T, Niikura N, Maeda S, Komoike Y, Bando H, Kanbayashi C, Iwata H. Tanaka K, et al. Among authors: tokunaga e. Breast Cancer. 2021 Jul;28(4):896-903. doi: 10.1007/s12282-021-01225-0. Epub 2021 Feb 18. Breast Cancer. 2021. PMID: 33599914 Free PMC article.
Effect of Trastuzumab Deruxtecan on QT/QTc Interval and Pharmacokinetics in HER2-Positive or HER2-Low Metastatic/Unresectable Breast Cancer.
Shimomura A, Takano T, Takahashi S, Sagara Y, Watanabe J, Tokunaga E, Shinkai T, Kamio T, Kikumori K, Kamiyama E, Fujisaki Y, Saotome D, Yamashita T. Shimomura A, et al. Among authors: tokunaga e. Clin Pharmacol Ther. 2023 Jan;113(1):160-169. doi: 10.1002/cpt.2757. Epub 2022 Oct 18. Clin Pharmacol Ther. 2023. PMID: 36164935 Free PMC article.
Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer.
Paluch-Shimon S, Neven P, Huober J, Cicin I, Goetz MP, Shimizu C, Huang CS, Lueck HJ, Beith J, Tokunaga E, Contreras JR, de Sant'Ana RO, Wei R, Shahir A, Nabinger SC, Forrester T, Johnston SRD, Harbeck N. Paluch-Shimon S, et al. Among authors: tokunaga e. Ther Adv Med Oncol. 2023 Feb 3;15:17588359231151840. doi: 10.1177/17588359231151840. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36756142 Free PMC article.
[Treatment of gastric cancer: current state and future prospect].
Maehara Y, Kakeji Y, Masuda T, Sakoguchi T, Imamura M, Ohgaki K, Taniguchi K, Sakurai M, Futatsugi M, Kimura Y, Nakamura T, Tokunaga E, Oki E, Ushiro S, Watanabe M, Oda S, Tanaka S, Baba H. Maehara Y, et al. Among authors: tokunaga e. Fukuoka Igaku Zasshi. 2003 Oct;94(10):285-95. Fukuoka Igaku Zasshi. 2003. PMID: 14689880 Free article. Review. Japanese. No abstract available.
Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma.
Tokunaga E, Oki E, Kimura Y, Yamanaka T, Egashira A, Nishida K, Koga T, Morita M, Kakeji Y, Maehara Y. Tokunaga E, et al. Breast Cancer Res Treat. 2007 Mar;101(3):249-57. doi: 10.1007/s10549-006-9295-8. Epub 2006 Sep 28. Breast Cancer Res Treat. 2007. PMID: 17006756
[FOXA1 expression in luminal-type breast cancer].
Tokunaga E, Hisamatsu Y, Maehara Y. Tokunaga E, et al. Nihon Rinsho. 2012 Sep;70 Suppl 7:438-42. Nihon Rinsho. 2012. PMID: 23350438 Japanese. No abstract available.
Gender differences in prognosis after esophagectomy for esophageal cancer.
Morita M, Otsu H, Kawano H, Kasagi Y, Kimura Y, Saeki H, Ando K, Ida S, Oki E, Tokunaga E, Ikeda T, Kusumoto T, Maehara Y. Morita M, et al. Among authors: tokunaga e. Surg Today. 2014 Mar;44(3):505-12. doi: 10.1007/s00595-013-0573-x. Epub 2013 Apr 6. Surg Today. 2014. PMID: 23563736
353 results